A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

NCT00670189 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Hedgehog Pathway
Smoothened
Basal Cell Carcinoma (BCC)
Basal Cell Nevoid Syndrome (BCNS)

Interventions

DRUG: BMS-833923 (XL139)

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]